EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A pilot program of HIV pre-exposure prophylaxis in Thai youth

Supattra Rungmaitree, Peerawong Werarak, Wadchara Pumpradit, Wanatpreeya Phongsamart, Keswadee Lapphra, Orasri Wittawatmongkol, Yuitiang Durier, Alan Maleesatharn, Beena Kuttiparambil, Tim R Cressey iD, Risa M Hoffman, Kulkanya Chokephaibulkit iD

PLOS ONE · 22.02.2024 · 19 (2) · e0298914

DOI: 10.1371/journal.pone.0298914 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 22.02.2024. Verfasst von Supattra Rungmaitree und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Pre-Exposure Prophylaxis, Sexual and Gender Minorities. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UNICEF BANGKOK THAILAND.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There are gaps in knowledge and experience of antiretroviral pre-exposure prophylaxis (PrEP) delivery in adolescents.

Methods

This pilot study enrolled Thai adolescents 14–20 year-old without HIV who reported risk behaviour. All participants were offered daily tenofovir/emtricitabine (TDF-FTC) and followed for 24 weeks. HIV testing, renal function, bone density scan, and sexually transmitted infection (STI) testing including syphilis serology and urine molecular testing for gonorrhoea and C . trachomatis were performed at baseline and weeks 12 and 24. Adherence was evaluated through intracellular tenofovir diphosphate (TFV-DP) levels in dried blood spots.

Results

Of the 61 enrolled adolescents, median age 18.1 (IQR: 14.8–20.9) years, 46 (75.4%) were males and 36 (59%) were MSM. Retention to week 24 was 80.3%. One third (36%) had TFV-DP levels consistent with taking ≥6 pills/week at week 12 and 29% at week 24. The factors associated with taking ≥6 pills/week were being MSM (adjusted odds ratio [aOR]: 53.2, 95% CI: 1.6–1811; p = 0.027), presence of STI at baseline (aOR: 9.4, 95% CI: 1.5–58.5; p = 0.016), and self-report of decreased condom use while taking PrEP (aOR: 8.7, 95% CI: 1.4–56.6; p = 0.023). 31% had an STI at baseline and this declined to 18% at week 24. No renal or bone toxicity was observed and there were no HIV seroconversions.

Conclusions

Daily oral PrEP with FTC-TDF in high-risk Thai adolescents is feasible, accepted, well-tolerated, and had no increased risk compensation; however, low adherence was a major challenge. Adolescent-specific PrEP strategies including long-acting modalities are needed for successful HIV prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsPre-Exposure ProphylaxisSexual and Gender MinoritiesOrganophosphatesMaleHumansAdolescentYoung AdultAdultFemalePilot ProjectsHomosexuality, MaleThailandEmtricitabineAdenine

Substanzen

Anti-HIV AgentsEmtricitabinetenofovir diphosphateAdenineOrganophosphates

Autor:innen und Institutionen

  • Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of preventive and social medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Bangkok Health Hub Medical Centre, Bangkok, Thailand.
  • UNICEF Thailand, Bangkok, Thailand.
  • PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
  • Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California, United States of America.

ORCID-Profile: Tim R Cressey, Kulkanya Chokephaibulkit

Förderung

  • UNICEF BANGKOK THAILAND

Zitieren

APA

Rungmaitree, S., Werarak, P., Pumpradit, W., Phongsamart, W., Lapphra, K., Wittawatmongkol, O., Durier, Y., Maleesatharn, A., Kuttiparambil, B., Cressey, T. R., Hoffman, R. M., & Chokephaibulkit, K. (2024). A pilot program of HIV pre-exposure prophylaxis in Thai youth. PLOS ONE, 19(2), e0298914. https://doi.org/10.1371/journal.pone.0298914

Vancouver

Rungmaitree S, Werarak P, Pumpradit W, Phongsamart W, Lapphra K, Wittawatmongkol O, et al. A pilot program of HIV pre-exposure prophylaxis in Thai youth. PLOS ONE. 2024;19(2):e0298914. doi:10.1371/journal.pone.0298914

BibTeX
@article{Rungmaitree2024,
  author = {Rungmaitree, Supattra and Werarak, Peerawong and Pumpradit, Wadchara and Phongsamart, Wanatpreeya and Lapphra, Keswadee and Wittawatmongkol, Orasri and Durier, Yuitiang and Maleesatharn, Alan and Kuttiparambil, Beena and Cressey, Tim R and Hoffman, Risa M and Chokephaibulkit, Kulkanya},
  title = {A pilot program of HIV pre-exposure prophylaxis in Thai youth},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {2},
  pages = {e0298914},
  doi = {10.1371/journal.pone.0298914}
}
Kostenlos starten →